Genzyme and Symbiomed form joint venture:
This article was originally published in Clinica
Executive Summary
Genzyme's General Division (US) and Symbiomed (Germany) are to form a 50:50 joint venture, Aristogen, to offer specialised genetic diagnostic services in Germany. The new company will offer prenatal and postnatal chromosome analysis by cytogenetic and fluorescent in situ hybridisation techniques. It will be based in Ingelheim, Germany. Symbiomed is itself a joint venture between the Leidenberger group and BioScientia, both in Germany.